← Back to Clinical Trials
Recruiting NCT07035314

NCT07035314 The Effect of Systemic Nonsteroidal Anti-inflammatory Drugs (NSAIDs) Vs Intraoperative Infiltration of Steroids in Tonsillar Bed Following Tonsillectomy on Post Tonsillectomy Pain.

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT07035314
Status Recruiting
Phase
Sponsor Ain Shams University
Condition Tonsillitis Chronic
Study Type INTERVENTIONAL
Enrollment 75 participants
Start Date 2025-03-08
Primary Completion 2025-07-01

Trial Parameters

Condition Tonsillitis Chronic
Sponsor Ain Shams University
Study Type INTERVENTIONAL
Phase N/A
Enrollment 75
Sex ALL
Min Age 4 Years
Max Age 10 Years
Start Date 2025-03-08
Completion 2025-07-01
Interventions
DexamethasoneNSAIDsControl (Standard treatment)

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

The aim of this study is to compare the efficacy of adding paracetamol to systemic non-steroidal anti-inflammatory drugs (NSAIDs) versus adding dexamethasone as local infiltration to paracetamol on post tonsillectomy pain control.

Eligibility Criteria

Inclusion Criteria: * Age: Between 4-10 years. * Indications of tonsillectomy such as: * Recurrent acute attacks at least 7 episodes in the past year or at least 5 episodes per year for 2 years or at least 3 episodes per year for 3 years. * Chronic tonsillitis and hypertrophy of tonsils causing sleep apnea, difficulty in deglutition, interference in speech. * Tonsillectomy by cold dissection only. * American Society of Anesthesiologists (ASA) classification 1,2 (Normal Health, Mild systematic disease). Exclusion Criteria: * Patients with age less than 4 and more than 10 years. * Indications of tonsillectomy other than chronic tonsillitis such as lymphoma. * Patients on chronic steroid therapy * Hemoglobin level less than 10 gm/dL * Presence of acute infection in the upper respiratory tract, acute tonsillitis * American Society of Anesthesiologists (ASA) classification ASA 3,4 (Severe systematic disease such as uncontrolled Diabetes, cardiac disease, liver or kidney disease, life threat

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology